Quantcast

Latest Acromegaly Stories

2014-07-29 08:32:23

-Primary efficacy results on track to be received by end of August 2014 TOORAK, Australia, July 29, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP") is pleased to report that dosing of all 26 patients in the Phase II trial of ATL1103 for the potentially life-threatening growth disorder, acromegaly has now been completed. There were no patient withdrawals or reports of any serious adverse events related to dosing with ATL1103. Patients will continue to be monitored for a...

2014-06-30 23:05:29

Dr. Yaron Moshel and ANS Discuss How to Recognize the Symptoms of Pituitary Tumors Morristown, NJ (PRWEB) June 30, 2014 Did you know pituitary tumors affect 15-20% of adults, and are caused by an abnormal growth of cells? How would you know you are suffering from one? Joe Lagitch, 71, of Parsippany has never been sick. His wife, Betty, a retired nurse, says she was surprised when her husband started to complain of headaches, but shrugged it off as a simple sinus infection. Two days later,...

2014-05-05 04:21:48

Acromegaly, an endocrine disorder resulting from elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels, is associated with high mortality(1,2) EAST HANOVER, N.J., May 5, 2014 /PRNewswire/ -- Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor(®) LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control. The study findings showed that patients taking...

2014-03-21 12:23:50

- 24 patients now recruited into the trial TOORAK, Australia, March 21, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP") is pleased to report that 24 acromegalic patients have been successfully enrolled and randomized to one of the two treatment regimens of dosing in the Phase II trial of ATL1103 for the growth disorder, acromegaly. This satisfies the necessary patient numbers proposed for the trial. Following from the positive results achieved from the interim...

2014-01-07 20:20:47

SAN FRANCISCO, Jan. 7, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to advise that it has been selected to present at the Biotech Showcase 2014 conference to be held January 13-15, 2014, at The Parc 55 Wyndham Hotel in San Francisco, CA. This is a significant opportunity for ANP to present to and engage with distinguished US-based investors, prospective partners, and key industry leaders, and in particular discuss the successful progress of...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related